Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024

Core Insights - Nurix Therapeutics, Inc. presented preclinical data on two drug candidates, NX-5948 and GS-6791, at ACR Convergence 2024, highlighting their potential in treating cancer and inflammatory diseases [1][2] Group 1: NX-5948 - NX-5948 is an orally available BTK degrader currently in a Phase 1b trial for B-cell malignancies and shows promise for treating inflammation and autoimmune diseases [1][5] - Preclinical data indicate that NX-5948 achieves superior suppression of BCR, TLR, and FcR signaling compared to existing BTK inhibitors, demonstrating efficacy in models of arthritis and other inflammatory diseases [2][4] - In models of collagen-induced arthritis, NX-5948 provided equal or superior clinical improvement and deeper suppression of plasma cell numbers compared to BTK inhibitors [2] Group 2: GS-6791 - GS-6791 is a selective, orally bioavailable degrader of IRAK4, developed in collaboration with Gilead Sciences for rheumatoid arthritis and other inflammatory diseases [1][6][7] - Preclinical data show that GS-6791 effectively inhibits IL-1 and TLR-induced cytokine release, demonstrating robust, dose-dependent efficacy in arthritis models [4][3] - The differentiated mechanism of action of GS-6791 compared to traditional kinase inhibitors positions it as a promising candidate for inflammatory conditions [3][4] Group 3: Company Overview - Nurix Therapeutics focuses on developing targeted protein modulation drugs for cancer and inflammatory diseases, leveraging its DELigase platform to create novel drug candidates [8] - The company aims to modulate cellular protein levels through E3 ligases, which play a crucial role in the ubiquitin-proteasome system [8] - Nurix's pipeline includes targeted protein degraders and inhibitors aimed at addressing significant challenges in treating autoimmune and inflammatory diseases [8]